

Petr G Lokhov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2744449/publications.pdf>

Version: 2024-02-01

53
papers

929
citations

471061

17
h-index

500791

28
g-index

56
all docs

56
docs citations

56
times ranked

1005
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4401.	1.8	2
2	Mass spectrometry-based metabolomics diagnostics —“ myth or reality?. <i>Expert Review of Proteomics</i> , 2021, 18, 7-12.	1.3	21
3	Antigenic Essence: Upgrade of Cellular Cancer Vaccines. <i>Cancers</i> , 2021, 13, 774.	1.7	6
4	Metabolomic Laboratory-Developed Tests: Current Status and Perspectives. <i>Metabolites</i> , 2021, 11, 423.	1.3	16
5	Personal Metabolomics: A Global Challenge. <i>Metabolites</i> , 2021, 11, 715.	1.3	4
6	Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson—™s Disease. <i>Metabolites</i> , 2021, 11, 14.	1.3	4
7	Comparative Metabolomic Study of <i>Drosophila</i> Species with Different Lifespans. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12873.	1.8	4
8	In Situ Mass Spectrometry Diagnostics of Impaired Glucose Tolerance Using Label-Free Metabolomic Signature. <i>Diagnostics</i> , 2020, 10, 1052.	1.3	0
9	Diagnosis of Parkinson—™s Disease by A Metabolomics-Based Laboratory-Developed Test (LDT). <i>Diagnostics</i> , 2020, 10, 332.	1.3	13
10	Parkinson—™s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization. <i>Diagnostics</i> , 2020, 10, 339.	1.3	20
11	Mass Spectrometry-Based Metabolomics Analysis of Obese Patients—™ Blood Plasma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 568.	1.8	23
12	Comparative Analysis of Skeletal Muscle Metabolites of Fish with Various Rates of Aging. <i>Fishes</i> , 2019, 4, 25.	0.7	8
13	Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2019, 16, 192-198.	0.2	4
14	Metabolomic diagnostics and human digital image. <i>Personalized Medicine</i> , 2019, 16, 133-144.	0.8	10
15	SANTAVACTM: Summary of Research and Development. <i>Vaccines</i> , 2019, 7, 186.	2.1	5
16	Evaluation of Dried Blood Spot Sampling for Clinical Metabolomics: Effects of Different Papers and Sample Storage Stability. <i>Metabolites</i> , 2019, 9, 277.	1.3	34
17	n-Butylamine for Improving the Efficiency of Untargeted Mass Spectrometry Analysis of Plasma Metabolite Composition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5957.	1.8	7
18	Assessing the Viability of Reintroduction of Locally Extinct Migratory Fish <i>Brycon orbignyanus</i> : Successful Growth, Dispersal and Maturation. <i>Fishes</i> , 2018, 3, 39.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Comparative Analysis of the Blood Plasma Metabolome of Negligible, Gradual and Rapidly Ageing Fishes. <i>Fishes</i> , 2018, 3, 46.	0.7	7
20	A Metabolomics Approach to Pharmacotherapy Personalization. <i>Journal of Personalized Medicine</i> , 2018, 8, 28.	1.1	54
21	Plasma Metabolome Signature in Patients with Early-stage Parkinson Disease. <i>Current Metabolomics</i> , 2018, 6, .	0.5	17
22	Label-free data standardization for clinical metabolomics. <i>BioData Mining</i> , 2017, 10, 10.	2.2	11
23	SANTAVAC \hat{a}, Φ : A Novel Universal Antigen Composition for Developing Cancer Vaccines. <i>Recent Patents on Biotechnology</i> , 2017, 11, 32-41.	0.4	2
24	Allogeneic Antigen Composition for Preparing Universal Cancer Vaccines. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	0.9	5
25	Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics. <i>Biomedical Reports</i> , 2016, 4, 122-126.	0.9	23
26	Mass spectrometry analysis of blood plasma lipidome as the method of disease diagnostics, evaluation of effectiveness and optimization of drug therapy. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2015, 9, 95-105.	0.2	3
27	Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 689-698.	1.4	13
28	OMICS for Tumor Biomarker Research. <i>Biomarkers in Disease</i> , 2015, , 3-30.	0.0	3
29	Prediction of classical clinical chemistry parameters using a direct infusion mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2015, 388, 53-58.	0.7	6
30	Diagnosing Impaired Glucose Tolerance Using Direct Infusion Mass Spectrometry of Blood Plasma. <i>PLoS ONE</i> , 2014, 9, e105343.	1.1	27
31	Mass spectrometry analysis of blood low-molecular fraction as a method for unification of therapeutic drug monitoring. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2014, 8, 1-10.	0.2	3
32	OMICS for Tumor Biomarker Research. , 2014, , 1-22.		0
33	Postgenomics Diagnostics: Metabolomics Approaches to Human Blood Profiling. <i>OMICS A Journal of Integrative Biology</i> , 2013, 17, 550-559.	1.0	39
34	Metabolic profiling of human blood. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2013, 7, 179-186.	0.2	13
35	Blood plasma metabolites and the risk of developing lung cancer in Russia. <i>European Journal of Cancer Prevention</i> , 2013, 22, 335-341.	0.6	34
36	Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 198-209.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Universal cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1549-1552.	1.4	8
38	Proteomic Footprinting of Drug-Treated Cancer Cells as a Measure of Cellular Vaccine Efficacy for the Prevention of Cancer Recurrence. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M1111.014480.	2.5	15
39	Diagnosis of lung cancer based on direct-infusion electrospray mass spectrometry of blood plasma metabolites. <i>International Journal of Mass Spectrometry</i> , 2012, 309, 200-205.	0.7	66
40	Metabolic fingerprinting of blood plasma from patients with prostate cancer. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2010, 4, 37-41.	0.2	12
41	Metabolite profiling of blood plasma of patients with prostate cancer. <i>Metabolomics</i> , 2010, 6, 156-163.	1.4	77
42	Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens. <i>Journal of Cancer</i> , 2010, 1, 230-241.	1.2	49
43	Proteolytically-cleaved Fragments of Cell Surface Proteins Stimulate a Cytotoxic Immune Response Against Tumor-activated Endothelial Cells In vitro. <i>Journal of Cancer Science & Therapy</i> , 2010, 02, 126-131.	1.7	15
44	Proteolytically-cleaved Fragments of Cell-surface Proteins from Live Tumor Cells Stimulate Anti-tumor Immune Response In vitro. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2010, 01, .	0.3	12
45	Cell proteomic footprint. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 680-682.	0.7	19
46	Distribution of tyrosinated and acetylated tubulin in centrioles during mitosis of 3T3 and SV40-3T3 cells. <i>Cell and Tissue Biology</i> , 2009, 3, 359-368.	0.2	3
47	Mass spectrometry methods in metabolomics. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2009, 3, 1-9.	0.2	14
48	Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. <i>Biochemistry (Moscow)</i> , 2006, 71, 354-360.	0.7	47
49	Proteomic and biochemical analysis of the mouse liver microsomes. <i>Toxicology in Vitro</i> , 2005, 19, 805-812.	1.1	21
50	Cytosolic Insulin-Binding Proteins Of Mouse Liver Cells. <i>Protein and Peptide Letters</i> , 2004, 11, 29-33.	0.4	4
51	Comparative Analysis of Different Typing Methods for <i>Helicobacter pylori</i> Clinical Isolates. <i>Biochemistry (Moscow)</i> , 2004, 69, 536-541.	0.7	3
52	Database search post-processing by neural network: Advanced facilities for identification of components in protein mixtures using mass spectrometric peptide mapping. <i>Proteomics</i> , 2004, 4, 633-642.	1.3	20
53	Comparative analysis of proteome maps of <i>Helicobacter pylori</i> clinical isolates. <i>Biochemistry (Moscow)</i> , 2003, 68, 42-49.	0.7	51